InternationalResearch and clinical trials
One-time gene editing treatment reduced hereditary angioedema attacks in a phase 3 trial
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
The HAELO study, published in NEJM, examined lonvoguran ziclumeran in hereditary angioedema. This is an experimental treatment that edits a gene inside the body using CRISPR. It is given as a single dose into a vein. In the 80-patient study, the monthly number of attacks was 87% lower than with placebo. The median follow-up was 7.5 months; the long-term effect is not yet known.
What does it mean for patients and families?
This treatment is not yet approved. Long-term safety data are awaited.
Source
Scientific paper: Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema. New England Journal of Medicine, 2026. DOI: 10.1056/NEJMoa2600931 · PubMed 42294842
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Hereditary angioedema (HAE)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.